Share-based Payment Arrangement, Expense of Fulgent Genetics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Fulgent Genetics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Fulgent Genetics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,717,000, a 11% decline year-over-year.
  • Fulgent Genetics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $40,714,000, a 11% decline year-over-year.
  • Fulgent Genetics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $44,481,000, a 3.6% increase from 2023.
  • Fulgent Genetics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $42,922,000, a 32% increase from 2022.
  • Fulgent Genetics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $32,640,000, a 106% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Fulgent Genetics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $40,714,000 $9,717,000 -$1,203,000 -11% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $41,917,000 $10,039,000 -$1,596,000 -14% 01 Apr 2025 30 Jun 2025 10-Q 01 Aug 2025 2025 Q2
Q1 2025 $43,513,000 $10,550,000 -$968,000 -8.4% 01 Jan 2025 31 Mar 2025 10-Q 02 May 2025 2025 Q1
Q4 2024 $44,481,000 $10,408,000 -$1,024,000 -9% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $45,505,000 $10,920,000 +$18,000 +0.16% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $45,487,000 $11,635,000 +$1,312,000 +13% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2025 2025 Q2
Q1 2024 $44,175,000 $11,518,000 +$1,253,000 +12% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2025 2025 Q1
Q4 2023 $42,922,000 $11,432,000 +$1,410,000 +14% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $41,512,000 $10,902,000 +$1,930,000 +22% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $39,582,000 $10,323,000 +$2,293,000 +29% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $37,289,000 $10,265,000 +$4,649,000 +83% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 $32,640,000 $10,022,000 +$5,002,000 +100% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q3 2022 $27,638,000 $8,972,000 +$4,598,000 +105% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $23,040,000 $8,030,000 +$4,504,000 +128% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $18,536,000 $5,616,000 +$2,654,000 +90% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $15,882,000 $5,020,000 +$2,017,000 +67% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $13,865,000 $4,374,000 +$1,224,000 +39% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $12,641,000 $3,526,000 +$2,446,000 +226% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $10,195,000 $2,962,000 +$2,038,000 +221% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $8,157,000 $3,003,000 +$2,065,000 +220% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $6,092,000 $3,150,000 +$2,199,000 +231% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $3,893,000 $1,080,000 +$343,000 +47% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $3,550,000 $924,000 +$341,000 +58% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $3,209,000 $938,000 +$340,000 +57% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $2,869,000 $951,000 +$363,000 +62% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $2,506,000 $737,000 +$164,000 +29% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $2,342,000 $583,000 +$38,000 +7% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $2,304,000 $598,000 +$17,000 +2.9% 01 Oct 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
Q3 2018 $2,287,000 $588,000 +$39,000 +7.1% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $2,248,000 $573,000 +$149,000 +35% 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2
Q1 2018 $2,099,000 $545,000 -$20,000 -3.5% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $2,119,000 $581,000 01 Oct 2017 31 Dec 2017 10-K 22 Mar 2019 2018 FY
Q3 2017 $549,000 -$1,944,000 -78% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $424,000 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018 2018 Q2
Q1 2017 $565,000 -$1,060,000 -65% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1
Q3 2016 $2,493,000 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q1 2016 $1,625,000 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1

Fulgent Genetics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $44,481,000 +$1,559,000 +3.6% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $42,922,000 +$10,282,000 +32% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $32,640,000 +$16,758,000 +106% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
2021 $15,882,000 +$7,725,000 +95% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $8,157,000 +$4,948,000 +154% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $3,209,000 +$905,000 +39% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $2,304,000 +$185,000 +8.7% 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
2017 $2,119,000 -$2,535,000 -54% 01 Jan 2017 31 Dec 2017 10-K 22 Mar 2019 2018 FY
2016 $4,654,000 -$3,502,000 -43% 01 Jan 2016 31 Dec 2016 10-K 20 Mar 2018 2017 FY
2015 $8,156,000 01 Jan 2015 31 Dec 2015 10-K 17 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.